Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.
The MICs and MBCs of ciprofloxacin were determined for clinical isolates of antibiotic-resistant aerobic bacteria. Decreased susceptibility to ciprofloxacin of cefotaxime- and amikacin-resistant Serratia marcescens and amikacin-resistant Pseudomonas aeruginosa strains were noted. The data suggest that ciprofloxacin susceptibility should be carefully monitored in treating patients with hospital-acquired bacterial infections.
D000583:Amikacin / Q000494:pharmacology*; D002439:Cefotaxime / Q000494:pharmacology*; D002939:Ciprofloxacin; D003428:Cross Infection / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008712:Methicillin / Q000494:pharmacology*; D010403:Penicillin Resistance; D011804:Quinolines / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects*
D011804:Quinolines; D007612:Kanamycin; D002939:Ciprofloxacin; D000583:Amikacin; D002439:Cefotaxime; D008712:Methicillin